Tag: Xerys

AS PART OF ITS INTERNATIONAL DEVELOPMENT, SKYTECH ANNOUNCES THE ACQUISITION OF AN INDUSTRIAL SITE IN POZZAGLIO ED UNITI, ITALY, TO SET UP ITS PRODUCTION OF PREMIUM RECYCLED PLASTICS

November 2 2022
News, Sustainable development

SKYTECH, la pépite française de la production de plastiques régénérés premium, annonce la production à grande échelle de ses polymères régénérés premium (rABS, rPS, rPP) issus de véhicules hors d’usage (VHU) et des déchets d’équipements électriques et électroniques (DEEE).

ADVANCED BIODESIGN ANNOUNCES THAT IT HAS OBTAINED FUNDING FOR ITS CRISPALDHin PROJECT AS PART OF THE RELAUNCH FRANCE PLAN

September 21 2022
Health, News

Cet expert de renommée internationale de la recherche en oncologie moléculaire contribuera avec les équipes d’Advanced BioDesign au développement du DIMATE, qui pourrait devenir une nouvelle thérapie ciblée de référence dans la prise en charge des cancers résistants

SKYTECH LAUNCHES ITS INTERNATIONAL DEPLOYMENT AND ANNOUNCES THE OPENING OF A FIRST SUBSIDIARY IN ITALY

July 7 2022
News, Sustainable development

ALZPROTECT AWARDED A GRANT FROM THE MICHAEL J. FOX FOUNDATION TO ADVANCE SMALL MOLECULE PARKINSON’S DISEASE PROGRAM

June 1 2022
Health, News

Cette délivrance renforce le portefeuille des brevets couvrant l’Ezéprogind et ses utilisations thérapeutiques déjà délivrés en Europe (EP 2 938 597 – validé dans 26 états membres de la Convention sur le Brevet Européen), et dans 11 autres pays incluant le Japon (JP 6384923) et la Chine (CN 105008333).

SKYTECH REVEALS A NEW GOVERNANCE TO ACCELERATE ITS DEVELOPMENT IN EUROPE AND INTERNATIONALLY

January 26 2022
News, Sustainable development

ALZPROTECT COMPLETES PHASE 2A CLINICAL TRIAL ENROLLMENT FOR AZP2006 IN PROGRESSIVE SUPRA NUCLEAR PALSY (PSP)

January 20 2022
Health, News

ALZPROTECT STRENGTHENS ITS INTELLECTUAL PROPERTY PORTFOLIO FOR ITS FIRST-IN-CLASS CLINICAL STAGE DRUG EZEPROGIND

November 23 2020
Health, News

ALZPROTECT, a biopharmaceutical company developing therapeutic solutions for neurodegenerative diseases announces today that the United States Patent and Trademark Office (USPTO) has recently granted patent number US 10,772,884 concerning the therapeutic uses of its first-in-class clinical stage drug Ezeprogind (AZP2006) in the treatment of tauopathies.

BIOLOG-ID LLC PARTNERS WITH LIFESERVE BLOOD CENTER TO IMPLEMENT CUTTING-EDGE BLOOD PRODUCT INVENTORY MANAGEMENT ECOSYSTEM

January 16 2020
Health, News

The Technology has the Potential to Become the Standard of Care for Blood Supply Chain Management

BIOLOG-ID RAISES 30 MILLION EUROS FROM FUNDS MANAGED BY XERYS

January 10 2020
Health, News

Biolog-id, a global leader in the traceability and management of sensitive health products (red blood cells, plasma, platelets and chemotherapy preparations), is announcing a campaign to raise 30 million euros from Xerys Funds